People · Operator
Named in public records as an officer, director or promoter · active 2009–2018 · Biotechnology, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Ideaya Biosciences, Inc. | — | Biotechnology | Series C | $111.4M | $3.9B | 2018 |
| Phaserx, Inc. | — | Biotechnology | Seed | $16.1M | $18.6M | 2009 |
| Ingenuity Systems Inc | — | Other Technology | Series B | $15.4M | $469.0M | 2010 |
| Ambrx Inc | — | Biotechnology | Series A | $10.0M | $361.5M | 2009 |
John D. Diekman at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside John D. Diekman on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Steven Gillis | 1 | 23 |
| Mark Wan | 1 | 10 |
| Timothy Shannon | 1 | 9 |
| Brian G. Atwood | 1 | 8 |
| David B Singer | 1 | 5 |
| Brian Daniels | 1 | 5 |
| Paul Stone | 1 | 5 |
| Jeffrey Stein | 1 | 4 |
| Terry Rosen | 1 | 4 |
| Paul H. Johnson | 1 | 3 |
| Stephen W. Kaldor | 1 | 3 |
| Yujiro Hata | 1 | 3 |
| John Diekman | 1 | 3 |
| Peter G. Schultz | 1 | 3 |
| Allan Marchington | 1 | 3 |
| Jacob Leschly | 1 | 2 |
| Shehan Dissanayake | 1 | 2 |
| Thilo P. Schroeder | 1 | 2 |
| Jim Swartz | 1 | 2 |
| PAUL W. JOHNSON | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.